What is Fu's subcutaneous needling?

Fu's subcutaneous needling, or FSN, is a China-invented acupuncture-related technique. A special trocar needle enters only the subcutaneous layer and moves in a fan-shaped motion. The patient then performs a brief resisted or active movement called the reperfusion approach. Unlike conventional acupuncture, the needle is not advanced into muscle.

What conditions is FSN used for?

The July 2026 Frontiers in Medicine review describes clinical use for musculoskeletal pain, postoperative pain, neuralgia and cancer pain, plus early research in irritable bowel syndrome, constipation and anorectal disorders. Evidence is uneven: most studies are small, many are Chinese-only, and standardized control groups are uncommon.

How much does Fu's subcutaneous needling cost in China?

A 2026 planning estimate is about US$20-$90 per session at Chinese public or private hospital programs, excluding travel, imaging, specialist consultation and medicines. A multi-session pain-rehabilitation plan may cost roughly US$150-$700. Final cost depends on hospital, city and clinical complexity.

Is FSN safer than deep needling?

FSN is designed to remain in the subcutaneous layer rather than muscle or deeper tissue. The 2026 review describes mainly mild events, including occasional subcutaneous hematoma. It still requires anatomical training and sterile technique; patients taking anticoagulants or with skin infection should disclose this before treatment.

Fu's Subcutaneous Needling in China: $20-$90 a Session for Pain and Rehabilitation

A peer-reviewed review published in Frontiers in Medicine on July 10, 2026 traces Fu's subcutaneous needling (FSN) from a China-invented treatment for soft-tissue pain into postoperative pain, neuralgia, cancer pain and early gastrointestinal rehabilitation research. The review searched Chinese and English literature published from January 2020 through December 2025. Its practical value is not a claim that FSN has solved chronic pain. It shows where the method is being used, how it differs from conventional acupuncture, and exactly where the evidence remains thin.

Why this story matters for an international patient. FSN is genuinely Chinese in origin: Professor Fu Zhonghua developed it in 1996 by combining acupuncture practice with anatomy, myofascial trigger-point work and active rehabilitation. The procedure stays in the subcutaneous layer, uses a distinctive fan-shaped movement, and pairs the needle with patient movement. A typical China planning estimate is US$20-$90 per session, but the evidence is condition-specific and much of it comes from small Chinese studies. It should be booked through a licensed hospital pain, rehabilitation or acupuncture department, not treated as a substitute for diagnosis or standard pain care.

What FSN is, and why it is not conventional acupuncture

Conventional acupuncture commonly uses fine stainless-steel needles inserted vertically or obliquely toward a named acupoint, with lifting, thrusting or rotation. FSN uses a dedicated trocar-style device made of a needle core, soft tube and protective tube. The clinician advances it parallel to the skin or at a shallow angle and keeps it above muscle. Once the tip reaches the subcutaneous plane, the clinician moves it from side to side in a controlled fan pattern.

The second part is the "reperfusion approach." With the needle in place, the patient actively contracts, stretches or resists movement involving the suspected tight muscle. In a low-back protocol, for example, the patient may complete a short cycle of resisted trunk or leg movement after about two minutes of swaying. In a knee protocol, the movement may be dorsiflexion plus knee flexion and extension. This active component makes FSN look closer to a combined needling-and-rehabilitation session than to a passive acupuncture appointment.

The Frontiers review describes two working ideas. The first is the "tightened muscle" model: abnormal muscle tension, impaired local blood supply and myofascial trigger points can sustain pain or dysfunction. The second is local reperfusion. Mechanical stimulation and movement may alter blood flow, lymphatic flow and neural signaling around the fascia. These are proposed mechanisms. The review does not prove that every clinical effect runs through them, and it does not establish a single neuro-endocrine pathway for every disease now listed under FSN.

What the 2026 Frontiers review found

The authors searched CNKI, Wanfang, PubMed and Cochrane for pain and non-pain FSN literature from 2020 to 2025, then summarized case reports, clinical studies and animal experiments. They divide the method into three phases:

FSN 1.0: soft-tissue and musculoskeletal pain, especially low-back, shoulder-neck and knee problems.
FSN 2.0: postoperative pain, neuralgia and cancer pain.
FSN 3.0: early work in irritable bowel syndrome, constipation and anorectal conditions, with a proposed neuro-endocrine-immune connection.

The strongest clinical story is still pain and movement. The review describes chronic low-back protocols using about 200 fan-shaped sweeps over two minutes, followed by active movement. It also summarizes knee osteoarthritis studies in which clinicians selected a tight muscle around the knee, used shallow insertion, then added resisted movement. A randomized single-blinded knee study reported durable improvement, while ultrasound elastography studies in neck pain found measurable changes in upper-trapezius thickness and elasticity after treatment.

The gastrointestinal work is newer and harder to interpret. In one irritable-bowel cohort, 33 patients received FSN twice weekly for six weeks and had improvements in visceral-sensitivity and quality-of-life scores; two developed mild subcutaneous hematomas. Constipation studies often combined FSN with herbs, biofeedback, probiotics or prucalopride. Those combinations are clinically realistic in an integrated Chinese Western medicine department, but they make it difficult to isolate how much benefit came from the needle.

The evidence gap is part of the news

The review's limitation section is unusually direct. Clinical trials remain scarce. Many have small samples, enroll only Chinese patients and do not use a widely accepted sham or standard-control procedure. Multi-center trials, longer follow-up, real-world cohorts and properly controlled randomized trials are still needed.

That caveat matters because some included studies report very high "effective rates." Chinese clinical papers have historically used composite response categories that do not always map cleanly onto Western endpoints such as a 30% pain reduction, the Brief Pain Inventory or a validated quality-of-life score. An international patient should ask the treating department what it measures before and after treatment: pain score, range of motion, walking tolerance, bowel frequency, analgesic use or a disease-specific quality-of-life tool. "Effective" without a defined endpoint is not enough.

Cancer pain deserves even tighter calibration. The paper discusses FSN as a non-drug adjunct. It should not displace opioids, radiotherapy, nerve blocks, tumor-directed treatment or palliative-care review. For postoperative pain, clinicians must first rule out infection, bleeding, thrombosis, mechanical failure and other causes that need surgical management.

Where FSN fits inside Chinese hospital care

The distinctive Chinese feature is not merely the needle. It is the departmental setting. At a tertiary Chinese hospital, FSN may sit inside an acupuncture, pain, rehabilitation, orthopedics or integrated Chinese Western medicine service. That allows the clinician to combine a Western diagnosis and imaging review with TCM modalities such as acupuncture, moxibustion, tuina or Chinese herbal medicine when appropriate.

For international patients, start with a hospital that has both a dedicated international service and a high-volume pain or rehabilitation department. Reasonable institutions to ask include Jiangsu Province Hospital of Chinese Medicine and Nanjing University of Chinese Medicine-affiliated services, where Professor Fu's technique has strong regional roots; Dongzhimen Hospital of Beijing University of Chinese Medicine; Shanghai Yueyang Hospital of Integrated Traditional Chinese and Western Medicine; and Guangdong Provincial Hospital of Chinese Medicine. Availability varies by department and physician roster. Ask the coordinator to confirm "Fu's subcutaneous needling" or "FSN" in writing rather than booking generic acupuncture and assuming the technique will be offered.

Patients from Indonesia, Vietnam, Malaysia, Russia and Central Asia usually get more value by embedding FSN in a diagnosis-led rehabilitation plan. A two-week trip can include specialist assessment, imaging review, three to six sessions, a home exercise plan and a bilingual discharge summary. Traveling to China solely for one session rarely makes economic or clinical sense.

2026 cost comparison and planning range

The table below uses 2026 planning estimates based on public Chinese treatment prices and international-department markups. Hospitals do not publish one national FSN tariff. Final cost depends on city, hospital, imaging needs and clinical complexity; the figures exclude flights and accommodation.

Service	China 2026 estimate	Regional comparison
FSN treatment session	US$20-$90	Specialist acupuncture or dry-needling visits in Singapore commonly cost more per visit
3-8 session rehabilitation plan	US$150-$700	Comparable private pain-rehabilitation packages vary widely across Singapore, Thailand and Korea
Initial international-department specialist review	US$40-$200	Imaging, laboratory tests and medicines are separate
Optional TCM adjuncts	US$15-$80 per session or prescription	May include conventional acupuncture, tuina, moxibustion or a prescribed herbal formula

Price alone should not drive the decision. A cheaper clinic without sterile technique, anatomical training or access to imaging is a poor bargain. FSN passes close to superficial vessels and nerves even though it remains above muscle. The treating clinician should know the patient's diagnosis, anticoagulant use, prior surgery and skin condition before inserting the needle.

What the patient pathway looks like

Send records first. Provide the diagnosis, recent imaging report, operation notes if relevant, medication list and a short account of what movement triggers the symptom.
Ask for the department, not just the hospital. Request pain medicine, rehabilitation, orthopedics or acupuncture with confirmed FSN experience.
Define the endpoint. Agree on a measurable target such as pain on movement, walking distance, joint range, bowel frequency or analgesic use.
Book a short reassessment window. If two or three sessions produce no measurable change, the department should reconsider the diagnosis or technique rather than sell a long package.
Leave with continuity documents. Ask for an English discharge summary, the exact FSN protocol, adverse events, exercises and advice for the home clinician.

For logistics, the hospital appointment guide explains medical-record submission and bilingual coordination. Patients comparing institutions can use the international-patient hospital guide. Russian-speaking patients can also review the Russian-language entry page.

Who should pause before booking

Do not book FSN as first-line care for unexplained severe pain, new weakness, bowel or bladder dysfunction, fever, suspected fracture, active postoperative bleeding or rapidly worsening cancer symptoms. Those need diagnosis first. Patients taking anticoagulants or antiplatelet drugs, people with bleeding disorders, active skin infection, severe needle phobia or poor wound healing need a clinician-led risk review.

Minor bruising or a small subcutaneous hematoma can occur. The review did not identify a broad serious-adverse-event signal, but that should not be translated into "risk free." The technique depends on precise control of depth and direction. A hospital should use single-use sterile equipment and document who performed the procedure.

What to watch next

The next useful research step is not another uncontrolled case series. The field needs multi-center trials with a credible control procedure, standardized FSN training, condition-specific outcomes and follow-up beyond the immediate post-treatment period. A low-back trial should report pain and function at three to twelve months. A postoperative study should report opioid use, mobilization and complications. Gastrointestinal studies must separate FSN from herbs, medication and biofeedback or use factorial designs that can distinguish the components.

The July 2026 Frontiers paper gives the outside world an unusually complete map of a treatment developed in China and still delivered mainly through Chinese clinical networks. It also makes the uncertainty easy to see. That combination is useful: FSN is specific enough to investigate and accessible enough to book, but not mature enough to promise.